コンテンツへスキップ
MediciNova, Inc.
  Message from CEO
  Our Mission
  Company Profile
  Management Team
  History
  Ongoing Clinical Studies
    About MN-166 (Ibudilast)
    ALS
    Oncology / Glioblastoma
    DCM
    CIPN
    ARDS / Lung Injury
    About MN-001(Tipelukast)
    NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  Press Release
  Event
  Media Archive
  Annual Report
  SEC filing
  Stock Quote -TSE
  Stock Quote -Nasdaq
  Historical Price Lookup
  Investment Calculator
  Analyst Coverage
  Corporate Governance
  Information Request
  Corporate Presentation & Resarch Reports
    Progressive Multiple Sclerosis (Progressive MS)
    Amyotrophic Lateral Sclerosis (ALS)
    Oncology / Glioblastoma
    Substance Dependence and Addiction
    MN-166 (ibudilast) News Articles
    MN-166 (ibudilast) Publications
  MN-001 Presentation
  Contact Us
Japanese site
  • About Us
    • Message from CEO
    • Our Mission
    • Company Profile
    • Management Team
    • History
  • Clinical Development
    • Ongoing Clinical Trial
    • MN-166 (Ibudilast)
      • About MN-166 (Ibudilast)
      • ALS
      • Oncology / Glioblastoma
      • DCM
      • CIPN
      • ARDS / Lung Injury
    • MN-001 ( tipelukast)
      • About MN-001(Tipelukast)
      • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  • Investor Relations
    • News
    • Events
    • Presentations
    • Stock Quote & Chart
    • TSE Stock Quote
    • Analyst Coverage
    • Equity Research
    • SEC Filings
    • Annual Reports
    • Documents & Charters
    • Email Alerts
  • Presentation
    • Corporate Presentation and Equity Research Analyst Reports
    • MN-166 Presentation
      • Progressive Multiple Sclerosis (Progressive MS)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Oncology / Glioblastoma
      • Substance Dependence and Addiction
      • MN-166 (ibudilast) News Articles
      • MN-166 (ibudilast) Publications
    • MN-001 Presentation
  • Contact Us

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea

MN-001
2022.03.172024.08.15
Page Top
medicinova_en
MediciNova, Inc.

関連記事

MN-001

高中性脂肪血症を伴うNASH患者を対象とするMN-001のフェーズ2臨床治験プロトコルに対するFDAの承認通知受領のお知らせ

MN-029

MN-029 (デニブリン)二塩酸塩に対するヨーロッパにおける特許承認のお知らせ

MN-166

米国神経学会第70回年次総会におけるMN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験(SPRINT-MS)結果に関する発表のお知らせ

MN-166

MN-166 のグリオブラストーマ(神経膠芽腫)適応とするIND申請に対する承認通知受領のお知らせ

MN-001

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan

MN-166

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy
    • About Us
      • Message from CEO
      • Our Mission
      • Company Profile
      • Management Team
      • History
    • Clinical Development
      • Ongoing Clinical Trial
      • MN-166 (Ibudilast)
        • About MN-166 (Ibudilast)
        • ALS
        • Oncology / Glioblastoma
        • DCM
        • CIPN
        • ARDS / Lung Injury
      • MN-001 ( tipelukast)
        • About MN-001(Tipelukast)
        • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
    • Investor Relations
      • News
      • Events
      • Presentations
      • Stock Quote & Chart
      • TSE Stock Quote
      • Analyst Coverage
      • Equity Research
      • SEC Filings
      • Annual Reports
      • Documents & Charters
      • Email Alerts
    • Presentation
      • Corporate Presentation and Equity Research Analyst Reports
      • MN-166 Presentation
        • Progressive Multiple Sclerosis (Progressive MS)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Oncology / Glioblastoma
        • Substance Dependence and Addiction
        • MN-166 (ibudilast) News Articles
        • MN-166 (ibudilast) Publications
      • MN-001 Presentation
    • Contact Us
  • MediciNova, Inc.